Standalone Financial Results, Limited Review Report for December 31, 2016
Panacea Biotec Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 2016 Board Meeting Intimation for Results & Closure of Trading Window
Panacea Biotec Ltd has informed BSE that a Meeting of the Board of Directors of the Company is scheduled to be held on February 14, 2017, inter alia, to consider and approve the Unaudited financial Results (Provisional) for the quarter and nine months ended December 31, 2016.Further, pursuant to the provisions of Regulations 30 & 51 of the Listing Regulations, the trading window of the Company shall remain closed for all designated persons... Shareholding for the Period Ended December 31, 2016
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Panacea Biotec Limited
Panacea Biotec on Wednesday said the US Food and Drug Administration has approved the company's abbreviated new drug application for rizatritan benzoate orally disintegrating tablets of 5 mg and 10... Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT)
Panacea Biotec Ltd has informed BSE regarding a Press Release dated January 18, 2017 titled "Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT)". Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Panacea Biotec Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Panacea Biotech Raises Supply Of Life Saving Drug, Stocks Soar
Panacea Biotech shares surged as much as 9 per cent on Tuesday after the drug firm saidit has increased availability of life saving drug Cilamin250 capsules. Panacea Biotec Ensures Increased availability of Life Saving Drug Cilamin250 (D-Penicillamine IP 250mg) Capsules for Treatment of Wilson's disease in India
Panacea Biotec Ltd has informed BSE regarding a Press Release dated January 03, 2017 titled "Panacea Biotec Ensures Increased availability of Life Saving Drug Cilamin250 (D-Penicillamine IP 250mg) Capsules for Treatment of Wilson's disease in India". Panacea launches tetravalent vaccine easyfour-TT
Panacea Biotec has launched fully-liquid tetravalent vaccine easyfour-TT used for primary immunisation and as booster dose for diphtheria, tetanus, pertussis and Hib.The vaccine will protect infants... Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib
Panacea Biotec Ltd has informed BSE regarding a Press Release dated December 26, 2016 titled "Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib".